Phase II Study: iC9/CD5CAR/IL-15 NK Cells CD5-targeted immunotherapy

This Phase II trial by MD Anderson explores the safety and efficacy of consolidation therapy using iC9/CD5CAR/IL-15 natural killer cells—engineered to target CD5 on aggressive T-cell lymphomas—in patients in first remission, combined with lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and rituximab. The study aims to assess one-year progression-free survival in this novel immunotherapy approach; consolidation options are limited (± auto-SCT in select cases)—engineered NK consolidation aims to reduce early relapse.